Monia Orciani | Stem cells | Best Researcher Award

Prof Dr. Monia Orciani | Stem cells | Best Researcher Award

 

Profile

Education

On January 23, 2004, she was awarded a PhD in Biomedical Biotechnology from the Università Politecnica delle Marche. In 2001, she obtained her qualification as a Professional Biologist from the same institution. She completed her degree in Biological Sciences on March 10, 2000, graduating with top honors (110/110 cum laude).

Her native language is Italian. She is also proficient in English at the C1 level across listening, reading, interaction, speaking, and writing. She achieved the LanguageCert Level 2 Certificate in ESOL International (Speaking) (Expert C1) on January 20, 2023.

Work experience

Since July 15, 2019, she has been serving as an Associate Professor in the scientific-disciplinary sector BIO/17 – Histology at the Department of Clinical and Molecular Sciences, Università Politecnica delle Marche. She obtained her qualification as a Second-Tier Professor in Applied Biology (SSD 05/F1) on April 4, 2017, and later achieved First-Tier Professor qualification in Histology (SSD 05/H2) on November 18, 2020. Previously, she was a confirmed Researcher in Histology at the same department from April 13, 2015, following an initial appointment as a non-confirmed Researcher from November 1, 2011, to April 13, 2015. Before that, she held a research fellowship from June 3, 2011, to November 1, 2011, focusing on the use of stem cells in regenerative medicine. From June 1, 2010, to May 31, 2011, she was a research grant holder investigating skin-derived stem cells and their clinical prospects in regenerative therapy at the Department of Experimental and Clinical Medicine. Between November 1, 2003, and April 15, 2010, she conducted research on leukocyte ectoenzymes and their role in the pathogenesis, diagnosis, and treatment of selected human diseases at the Department of Molecular Pathology and Innovative Therapies – Histology. From July 16, 2001, to July 15, 2003, she held a research fellowship focused on monoclonal antibodies for in vivo applications at the Institute of Biology and Genetics. Her early experience includes an internship at the Institute of Biology, Genetics, and Biochemistry, University of Medicine and Surgery, Turin, from May 1, 2000, to December 1, 2000.

Teaching Experience

Since the academic year 2022/23, she has been the course leader for Histology in the Medicine and Surgery (MedTech) degree programme at the Università Politecnica delle Marche.

Since 2019/20, she has held the position of Histology lecturer within the integrated course Human Morphological Sciences for the Dental Hygiene degree programme at the same university.

She has also taught Histology within the integrated Histology-Anatomy-Physiology course for the Medical Radiology Techniques for Imaging and Radiotherapy degree programme during the academic years 2016/17–2018/19 and again in 2022/23.

Since 2022/23, she has been responsible for teaching Histology within the Morphology and Histology integrated course for the Midwifery degree programme.

Since 2017/18, she has been a Tutor for AFP (Basic Sciences and First Aid Area) in the Medicine and Surgery degree programme.

She has also been involved in structured and cross-disciplinary teaching for the PhD in Human Health and Biomedical Sciences since 2017/18.

Since 2017/18, she has led an elective teaching activity (ADE) titled “Biotechnologies for the Study of Normal Human Histology” in the Medicine and Surgery degree programme.

From 2019/20 to 2021/22, she taught Histology for the Dentistry and Dental Prosthetics degree programme.

Between 2016/17 and 2017/18, she was the English Language course leader for the Medical Radiology Techniques for Imaging and Radiotherapy degree programme.

She is proficient in Microsoft Office and holds an Expert C1 Level LanguageCert Certificate in ESOL International (Speaking), awarded on 20 January 2023.

In the academic year 2018/19, she taught Histology within the Biomedical Sciences 1 integrated course for the Physiotherapy degree programme.

Between 2017/18 and 2018/19, she led a seminar-based Histology course for the Dietetics degree programme.

Since 2016/17, she has been responsible for a seminar-based Histology course in the Nursing degree programme at the Fermo campus.

Between 2012/13 and 2018/19, she taught Histology within the Histology-Anatomy integrated course for the Biomedical Laboratory Techniques degree programme.

Since 2012/13, she has also been responsible for a seminar-based Histology course in the Nursing degree programme at the Macerata campus.

Research project

Professor Monia Orciani has been recognised with the ImmunoTools IT-FlowISiAM-Award 2024 for her research on “Searching for New Targets for Alzheimer’s Disease.” She is the Principal Investigator (PI) of the PRIN 2022 project titled “The Effects of Cortisol Excess on Neurogenesis in Alzheimer’s Disease: A Mandatory Footpath through Stem Cells (FORGETFUL)” (Project ID: 2022XF7XZF). In 2022, she secured funding from Boehringer-Ingelheim for a study on the “Role of Nintedanib on Mesenchymal Stem Cells Derived from Patients with Idiopathic Pulmonary Fibrosis (IPF),” in collaboration with Professor Martina Bonifazi. Additionally, she received the Fondo di Finanziamento Attività di Base di Ricerca (FFABR) – FFO grant in 2017 for her research on “Inflammation and Stem Cells: New Associations.” Her work on stem cells also led to a strategic university project (2017–2019) investigating “The Role of Stem Cells in Cutaneous Repair Deficiency in Patients with Endogenous and Exogenous Cushing’s Syndrome.”

Professor Orciani has contributed to several national research initiatives, including PRIN 2017, where she collaborated on “The Impact of Glucocorticoid Circadian Rhythm Disruption on Cardiovascular Risk and Immune Dysfunction: Pathophysiology and Novel Biomarkers of Glucocorticoid Exposure in Hypercortisolism and Hypocortisolism (CHRONO-IMAGE),” led by Professor Rosario Pivonello (Project ID: 2017HRTZYA_005). Earlier in her career, she was involved in FIRB-funded projects, such as the 2011 study on “Molecular Markers for Diagnosis, Prognosis, and the Development of New Therapeutic Strategies for Adrenal Carcinoma” (PI: Professor Roberto Di Primio, Project ID: RBAP1153LS_004) and the 2010 preclinical evaluation of “Scaffolds for Skeletal Tissue Regeneration” (PI: Professor Roberto Giardino, Project ID: RBAP10MLK7_003). In 2010, she participated in a PRIN project examining “The Interaction between Glucose and Bone Metabolism for the Cardiometabolic Characterisation of a Population of Young Obese Individuals” (PI: Professor Roberto Di Primio, Project ID: 201098WFZ2_006). Her involvement in FIRB dates back to 2001, where she contributed to a study on “Leukocyte Ectoenzymes and Their Role in the Pathogenesis, Diagnosis, and Therapy of Selected Human Diseases” (PI: Professor Fabio Malavasi, Project ID: RBNE01N4Z9_003).

Publication

  • 1. Pisciotta A, Di Tinco R, Bertani G, Orlandi G, Bertoni L, Pignatti E, Orciani M, Sena P,
    Bertacchini J, Salvarani C, Carnevale G. Human dental pulp stem cells (hDPSCs) promote the
    lipofibroblast transition in the early stage of a fibro-inflammatory process. Front Cell Dev Biol.
    2023;11:1196023
  • Preziuso A, Piccirillo S, Cerqueni G, Serfilippi T, Terenzi V, Vinciguerra A, Orciani M, Amoroso
    S, Magi S, Lariccia V. Exploring the Role of NCX1 and NCX3 in an In Vitro Model of
    Metabolism Impairment: Potential Neuroprotective Targets for Alzheimer’s Disease. Biology
    (Basel). 2023;12:1005.
  • Di Vincenzo M, Diotallevi F, Piccirillo S, Carnevale G, Offidani A, Campanati A, Orciani M.
    miRNAs, Mesenchymal Stromal Cells and Major Neoplastic and Inflammatory Skin Diseases:
    A Page Being Written: A Systematic Review. Int J Mol Sci. 2023;24:8502.
  • Di Vincenzo M, Orciani M. Special Issue “The Role of Mesenchymal Stem Cells on
    Inflammatory and Fibrotic Diseases”. Int J Mol Sci. 2023;24:8578.
  • Di Vincenzo M, Martino M, Lariccia V, Giancola G, Licini C, Di Benedetto G, Arnaldi G,
    Orciani M. Mesenchymal Stem Cells Exposed to Persistently High Glucocorticoid Levels
    Develop Insulin-Resistance and Altered Lipolysis: A Promising In Vitro Model to Study
    Cushing’s Syndrome. Front Endocrinol (Lausanne). 2022;13:816229

Natalia Baran | Cancer Research | Best Researcher Award

Assist. Prof. Dr. Natalia Baran | Cancer Research | Best Researcher Award

Leading Attending at InselSpital Bern, Switzerland.

Dr. Natalia Baran is an Assistant Professor in the Department of Leukemia at MD Anderson Cancer Center, where she focuses on developing novel therapeutic strategies targeting metabolic vulnerabilities in leukemia. Her expertise lies in understanding how metabolic reprogramming can lead to drug resistance and contribute to leukemia progression. With a medical background and extensive experience in both clinical and research settings, Dr. Baran has been at the forefront of studies that aim to modulate metabolic pathways to enhance anti-leukemic responses. By combining insights from molecular biology, immunology, and clinical practice, she is actively working toward discovering innovative treatments for leukemia. Dr. Baran’s research holds great promise in advancing leukemia therapy, particularly by targeting metabolic reprogramming in the context of therapy resistance. Her multidisciplinary approach, integrating clinical data with laboratory research, makes her a key figure in leukemia research.

Profile

Scopus

Google Scholar

Orcid

Education:

Dr. Natalia Baran completed her undergraduate studies in Biotechnology, earning a Master of Science degree in 2006 from Wroclaw University of Science and Technology in Poland. She further pursued medical education and obtained her Medical Doctor (MD) degree from Wroclaw Medical University in 2007. Driven by her passion for research, Dr. Baran earned a Ph.D. in Medicine from the University of Bonn in 2015. Her doctoral research laid the foundation for her current focus on leukemia and metabolic reprogramming. In addition, Dr. Baran underwent extensive postdoctoral training at MD Anderson Cancer Center, where she honed her expertise in hematology and oncology, contributing significantly to translational research in leukemia. Her diverse educational background, blending science and medicine, has shaped her comprehensive approach to cancer research.

Professional Experience:

Dr. Baran has a rich professional experience that bridges clinical practice and cutting-edge research. After completing her MD, she pursued clinical residencies in Internal Medicine, Hematology, and Oncology at prestigious German institutions, including the University of Heidelberg and the University of Bonn. This clinical experience laid the groundwork for her subsequent focus on leukemia research. In 2016, she joined MD Anderson Cancer Center as a Postdoctoral Fellow in the Department of Leukemia. During her postdoctoral tenure, Dr. Baran worked closely with Dr. Marina Konopleva, exploring the role of metabolic pathways in leukemia resistance. By 2022, she had transitioned to an Assistant Professor role, continuing her translational research in leukemia, with a particular emphasis on identifying novel therapeutic strategies. Her clinical and research experiences synergize to enhance her contributions to the leukemia research community.

Research Interests:

Dr. Baran’s research is primarily centered on exploring metabolic vulnerabilities and their role in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Her work seeks to understand the mechanisms through which metabolic reprogramming in leukemia cells contributes to drug resistance and tumor progression. Dr. Baran is particularly interested in how modulating the metabolic environment can enhance the effectiveness of leukemia therapies. By focusing on the interplay between metabolism and leukemic cell survival, she aims to identify new therapeutic strategies that target metabolic pathways to overcome resistance to traditional treatments. Her research also explores how immune modulation can be integrated with metabolic interventions to develop more efficient leukemia therapies.

Awards and Honors:

Dr. Baran has received recognition for her contributions to leukemia research, although specific awards are not detailed in available sources. However, her research has been featured prominently in major scientific forums, including the Annual Metabolism in Cancer Symposium organized by MD Anderson. Her work has earned her respect within the scientific community, as evidenced by her continued role as an Assistant Professor and her involvement in prestigious cancer research initiatives. Dr. Baran’s impact is evident in her ongoing efforts to bridge the gap between basic science and clinical application, aiming to revolutionize leukemia treatment.

Skills:

Dr. Baran’s research skills encompass a wide range of techniques in molecular biology, cell culture, and metabolic analysis. She is highly proficient in studying the metabolic pathways that drive leukemia, using state-of-the-art technologies such as high-resolution metabolic flux analysis, RNA sequencing, and advanced cell imaging. Dr. Baran is skilled at integrating basic science with clinical data, ensuring that her research translates into practical therapeutic interventions. Her expertise in immunology further complements her research in leukemia, allowing her to investigate the potential of combining metabolic therapies with immune modulation to improve patient outcomes. Her interdisciplinary approach is a key strength in her ongoing work in leukemia research.

Publication Top Notes

A Selective BCL-XL PROTAC Degrader Achieves Safe and Potent Antitumor Activity

  • Authors: S Khan, X Zhang, D Lv, Q Zhang, Y He, P Zhang, X Liu, D Thummuri, et al.
  • Journal: Nature Medicine
  • Volume: 25(12), Pages 1938–1947
  • Cited by: 515
  • Year: 2019

Targeting a Cytokine Checkpoint Enhances the Fitness of Armored Cord Blood CAR-NK Cells

  • Authors: M Daher, R Basar, E Gokdemir, N Baran, N Uprety, AK Nunez Cortes, et al.
  • Journal: Blood, The Journal of the American Society of Hematology
  • Volume: 137(5), Pages 624–636
  • Cited by: 226
  • Year: 2021

Inhibiting Glutaminase in Acute Myeloid Leukemia: Metabolic Dependency of Selected AML Subtypes

  • Authors: P Matre, J Velez, R Jacamo, Y Qi, X Su, T Cai, SM Chan, A Lodi, et al.
  • Journal: Oncotarget
  • Volume: 7(48), Pages 79722
  • Cited by: 194
  • Year: 2016

Complex I Inhibitor of Oxidative Phosphorylation in Advanced Solid Tumors and Acute Myeloid Leukemia: Phase I Trials

  • Authors: TA Yap, N Daver, M Mahendra, J Zhang, C Kamiya-Matsuoka, et al.
  • Journal: Nature Medicine
  • Volume: 29(1), Pages 115–126
  • Cited by: 182
  • Year: 2023

Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy

  • Authors: N Baran, M Konopleva
  • Journal: Clinical Cancer Research
  • Volume: 23(10), Pages 2382–2390
  • Cited by: 126
  • Year: 2017

Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood–Derived NK Cells Facilitates CAR-Like Responses Against CD30+ Malignancies

  • Authors: LN Kerbauy, ND Marin, M Kaplan, PP Banerjee, MM Berrien-Elliott, et al.
  • Journal: Clinical Cancer Research
  • Volume: 27(13), Pages 3744–3756
  • Cited by: 117
  • Year: 2021

Clonal Selection and Therapy Resistance in Acute Leukemias: Mathematical Modelling Explains Different Proliferation Patterns at Diagnosis and Relapse

  • Authors: T Stiehl, N Baran, AD Ho, A Marciniak-Czochra
  • Journal: Journal of The Royal Society Interface
  • Volume: 11(94), Article ID 20140079
  • Cited by: 106
  • Year: 2014

Activation of RAS/MAPK Pathway Confers MCL-1 Mediated Acquired Resistance to BCL-2 Inhibitor Venetoclax in Acute Myeloid Leukemia

  • Authors: Q Zhang, B Riley-Gillis, L Han, Y Jia, A Lodi, H Zhang, S Ganesan, R Pan, et al.
  • Journal: Signal Transduction and Targeted Therapy
  • Volume: 7(1), Article ID 51
  • Cited by: 104
  • Year: 2022

Conclusion:

Dr. Natalia Baran is a prominent researcher whose work in leukemia has the potential to transform therapeutic approaches, especially through targeting metabolic pathways. Her strong academic background, combined with extensive clinical and research experience, enables her to address one of the most pressing challenges in leukemia treatment: drug resistance. By focusing on metabolic reprogramming, Dr. Baran is paving the way for innovative strategies to combat leukemia and improve patient outcomes. Her expertise in integrating basic research with clinical applications ensures that her contributions will have a lasting impact on the field of oncology, particularly in the development of new, more effective therapies for leukemia.